Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).
Sponsor: Boehringer Ingelheim
Listed as NCT00563381, this PHASE4 trial focuses on Pulmonary Disease, Chronic Obstructive and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
AR Crimea, Ukraine , Aachen, Germany , Aalen, Germany , Adana, Turkey (Türkiye) , Afula, Israel , Alytus, Lithuania , Angra do Heroísmo, Portugal , Ankara, Turkey (Türkiye) , Arkhangelsk, Russia , Ashkelon, Israel and 487 more locations